Johnson & Johnson (NYSE: JNJ) saw its stock price increase today, as a string of positive regulatory developments and upbeat analyst commentary outweighed concerns over potential tariffs and device safety alerts. Key factors influencing the share movement include:
Positive Sentiment:
Submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking approval of CAPLYTA® (lumateperone) for relapse prevention in schizophrenia after Phase 3 data showed a 63% reduction in relapse risk compared to placebo.
Supplemental new drug application submitted to U.S. FDA for CAPLYTA
Positive Sentiment:
Defeated generic drugmakers in a U.S. appeals court, preserving exclusivity for its schizophrenia treatment.
J&J defeats generic drugmakers in US appeal over schizophrenia treatment
Positive Sentiment:
A Money Morning analysis projects JNJ shares could jump to $158 by next week, citing momentum from recent drug filings.
Why JNJ Could Jump to $158 by Next Week
Positive Sentiment:
Named one of the top “Dogs of the Dow” dividend stocks for July, highlighting its attractive yield among large‐cap names.
Dogs of the Dow: These Are The Best Dividend Stocks in July 2025
Positive Sentiment:
Zacks highlights J&J as a strong momentum stock based on favorable style scores.
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Neutral Sentiment:
Wells Fargo maintains a Hold rating and a $170 price target, citing MedTech growth balancing pharmaceutical challenges.
Balanced Outlook on Johnson & Johnson: MedTech Growth vs. Pharmaceutical Challenges
Neutral Sentiment:
Zacks asks whether J&J’s Q2 results will reflect the end of MedTech headwinds and deliver higher sales ahead of earnings.
Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?
Neutral Sentiment:
Featured among “3 Must‐Buy Dividend Stocks if You Only Have $5,000 to Spend,” underscoring its appeal to income‐focused investors.
3 Must-Buy Dividend Stocks if You Only Have $5,000 to Spend
Negative Sentiment:
President Trump threatened tariffs of up to 200% on imported pharmaceuticals “very soon,” potentially raising costs for JNJ, though implementation may be delayed by 12–18 months.
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Negative Sentiment:
The FDA issued an early alert for safety concerns over Abiomed’s Impella heart pump controllers—part of J&J’s device portfolio—after reports of three patient deaths.
FDA Issues Early Alert For Johnson & Johnson's Abiomed Heart Pump Controllers
Posted 6h ago
AI Generated. May Contain Errors.